A double blind, placebo-controlled, dose-ranging study to investigate the effect on glycemic control, safety, pharmacokinetics and pharmacodynamics of GLP-1 [glucagon-like peptide 1; taspoglutide; R 1583] in patients with type 2 diabetes mellitus treated with a stable dose of metformin

Trial Profile

A double blind, placebo-controlled, dose-ranging study to investigate the effect on glycemic control, safety, pharmacokinetics and pharmacodynamics of GLP-1 [glucagon-like peptide 1; taspoglutide; R 1583] in patients with type 2 diabetes mellitus treated with a stable dose of metformin

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Taspoglutide (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2009 Actual end date changed from Jun 2007 to Nov 2007 as reported by ClinicalTrials.gov.
    • 10 Jun 2008 Results have been presented at the American Diabetes Association (ADA) 2008, according to a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top